🦋 In The News Decreased Survival for Prostate Cancers With dMMR ▫️For men with advanced prostate cancer who have certain genomic mutations, overall survival (OS) is roughly half that of patients who do not have the genetic anomalies, according to a new study that aims to refine the ways in which such mutations are identified. ▫️The study was published online September 4 in the Journal of Clinical Investigation. ▫️In the analysis, 8.1% of a cohort of 124 men with advanced disease had defective mismatch repair (dMMR) cancers, which means they may have benefited from immune checkpoint–inhibiting therapies, report Daniel Nava Rodrigues, MD, of the Institute of Cancer Research, London, United Kingdom, and international colleagues. ▫️In the United States, the checkpoint inhibitor pembrolizumab (Keytruda, Merck) was approved in 2017 for use in all dMMR tumors and all tumors with a high degree of microsatellite instability (MSI-H). - This approval was hailed as a milestone, as it was the first time that a drug was approved for use in a specific genetic mutation regardless of the site of the cancer. Such drugs are termed tissue-agnostic antitumor agents. - The dMMR amd MSI-H defects are found most commonly in colorectal, endometrial, and gastrointestinal cancers; they appear less commonly in other cancers, including those of the prostate. ▫️Advanced prostate cancer was defined as metastatic castration-resistant disease, meaning that the disease had progressed despite hormone therapy. We Dr.vijay Sharma harshu8696@gmail.com 7976487464
